Teva's ANDA for Provigil entitled to 180-day exclusivity

Teva Pharmaceutical Industries Ltd. announces that the FDA has decided that its wholly owned subsidiary, Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil® (modafinil) and therefore Teva's ANDA alone is entitled to 180-day exclusivity. Cephalon launched generic Provigil® on March 29, 2012 and the FDA has also decided that such launch triggered the exclusivity.

Teva expects Par Pharmaceutical to launch a second generic product on April 6th pursuant to the agreement with the FTC in connection with the Cephalon acquisition.


Teva Pharmaceutical Industries Ltd.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Researchers make an incredible discovery about mammalian brains